1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,500 | 13,000 | 08:13 | |
| 12,500 | 12,900 | 07:31 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Carlsmed promotes Jeff Bertolini to COO to support spine surgery growth | 1 | Seeking Alpha | ||
| Di | Carlsmed, Inc. Announces Chief Operating Officer Appointment | 116 | GlobeNewswire (Europe) | CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions... ► Artikel lesen | |
| Di | CARLSMED, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.08. | Carlsmed auf Konferenz der Bank of America: Bessere Medicare-Vergütung als Wachstumstreiber | 6 | Investing.com Deutsch | ||
| 06.08. | Truist raises Carlsmed stock price target on strong growth outlook | 1 | Investing.com | ||
| 06.08. | Carlsmed outlines $74M-$78M 2026 revenue outlook as CMS finalizes new aprevo lumbar MS-DRGs effective October 1 | 1 | Seeking Alpha | ||
| 05.08. | Carlsmed steigert Umsatz im zweiten Quartal 2026 um 57 %, Aktie reagiert kaum | 1 | Investing.com Deutsch | ||
| CARLSMED Aktie jetzt für 0€ handeln | |||||
| 05.08. | Carlsmed Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance | 124 | GlobeNewswire (Europe) | Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 03.08. | Carlsmed Announces Favorable Reimbursement for aprevo lumbar Procedures | 163 | GlobeNewswire (Europe) | CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions... ► Artikel lesen | |
| 22.07. | Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026 | 2 | GlobeNewswire (USA) | ||
| 01.07. | Needham initiates Carlsmed stock with buy rating on implant differentiation | 2 | Investing.com | ||
| 01.07. | Needham startet Coverage für Carlsmed mit Kaufempfehlung dank differenzierter Implantate | 2 | Investing.com Deutsch | ||
| 03.06. | CARLSMED, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet | 2 | Zacks | ||
| 06.05. | Carlsmed raises FY 2026 revenue outlook to $72M-$77M as CMS proposes new MS-DRGs for aprevo lumbar | 1 | Seeking Alpha | ||
| 05.05. | Carlsmed, Inc. GAAP EPS of -$0.32, revenue of $16.1M | 3 | Seeking Alpha | ||
| 05.05. | Carlsmed Q1 2026 Earnings Call: Complete Transcript | 1 | Benzinga.com | ||
| 05.05. | Carlsmed Reports First Quarter 2026 Financial Results | 190 | GlobeNewswire (Europe) | First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 05.05. | CARLSMED, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.04. | Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026 | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDLINE | 28,000 | 0,00 % | Jim Cramer Names Medline (MDLN) a Sleeper Compounder | ||
| OMADA HEALTH | 18,200 | 0,00 % | Omada Health, Inc.: Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day | ||
| ADVANCED BIOMED | 7,980 | -2,56 % | Morning Market Movers: InMed Pharmaceuticals, INLIF Limited, China SXT Pharmaceuticals, Advanced Biomed See Big Swings | BEIJING (dpa-AFX) - At 8:30 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CUPRINA HOLDINGS | 3,150 | -0,94 % | Cuprina Holdings LTD - F-1/A, Registration statement for certain foreign private issuers | ||
| MINIMED GROUP | 19,412 | +0,11 % | MiniMed Group, Inc. - 10-Q, Quarterly Report | ||
| PARK DENTAL PARTNERS | 18,400 | 0,00 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| SHOULDER INNOVATIONS | 16,200 | 0,00 % | Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch | Second Product Introduction on New Line of Technologies for Metal-Sensitive Patients
GRAND RAPIDS, Mich., Sept. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc.... ► Artikel lesen | |
| TENON MEDICAL | 5,850 | -1,35 % | Tenon Medical Announces Warrant Inducement for Aggregate Gross Proceeds of Approximately $2,872,338 | LOS GATOS, CA / ACCESS Newswire / September 11, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain... ► Artikel lesen | |
| FRESENIUS | 45,040 | +0,75 % | UBS stuft Fresenius SE auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Fresenius mit einem Kursziel von 56 Euro auf "Buy" belassen. Analyst Graham Doyle hält die Sorgen um das US-Geschäft mit... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,230 | -0,49 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 38,440 | -0,13 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| PROGYNY | 27,350 | 0,00 % | Progyny auf Gesundheitskonferenz von Wells Fargo: Wachstumsperspektiven bleiben intakt | ||
| BRIGHTSPRING HEALTH SERVICES | 58,73 | 0,00 % | BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell? | ||
| LIFESTANCE HEALTH GROUP | 12,975 | +0,04 % | LifeStance Health Group, Inc. - 8-K, Current Report | ||
| HEARTFLOW | 49,850 | -0,06 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen |
Das Unternehmen CARLSMED INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 12,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARLSMED INC finden Sie auf Wallstreet Online.